Fatma Ketenci Gencer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fatma Ketenci Gencer has a total of 219 co-authors. Here are the top co-authors by number of shared publications:
- Semra Yüksel
Department of Obstetrics and Gynecology, Basaksehir Çam ve Sakura City Hospital, Istanbul, Turkey
6 shared publications Serkan Kumbasar
Department of Obstetrics and Gynecology, Gaziosmanpasa Training and Research Hospital, University Of Health Sciences, Istanbul, Turkey
5 shared publications- Serkan Kumbasar
Sakarya University
5 shared publications - Süleyman Salman
Department of Obstetrics and Gynaecology, Gaziosmanpaşa Training and Research Hospital, University of Health Sciences, Istanbul 34250, Turkey
5 shared publications - Burcu Dincgez
University of Health Sciences, Turkey
4 shared publications Suleyman Salman
Department of Obstetrics and Gynecology, Gaziosmanpasa Training and Research Hospital, University Of Health Sciences, Istanbul, Turkey
4 shared publications
Latest Publications
- Open Access
- 1 August 2026
- Published by National Institute for Health and Care Research in Health and Social Care Delivery Research
- p. 1-160
Individual Participant Data Meta-Analysis (IPDMA) of long-term COVID-19 outcomes in a systematic review-informed, international, multidisciplinary database
Background: Identifying and addressing long-term health and societal challenges after COVID-19 is a research priority. Objectives: To create an international, multidisciplinary COVID-19 database, and synthesise long-term outcomes, predictors and costs. Design: Systematic identification of COVID-19 data sets and meta-analysis of individual participant data on long-term outcomes after COVID-19. Setting: Contributed data were collected in clinical, community and research settings. Interventions: Interventions from original studies were included as covariates in models. Data sources: MEDLINE, Cochrane Central Register of Controlled Trials, EMBASE, Web of Science, PsycInfo ® (American Psychological Association, Washington, DC, USA), Cumulative Index to Nursing and Allied Health Literature, World Health Organization Global Index Medicus, Epistemonikos, LitCOVID; World Health Organization International Clinical Trials Registry Platform; ClinicalTrials.gov and supplementary searches for studies (November 2019–November 2021) were searched for studies on > 10 people from cohort, case-control, survey or randomised controlled trial studies, across any setting, describing validated assessment instruments, symptoms, hospitalisation, discharge destination or mortality beyond 28-days after COVID-19 onset. Data were extracted by two independent reviewers. Methods: Principal investigators contributed fully anonymised individual participant data. Demography, equity and symptoms were described. Assessment instruments were mapped to the International Classification of Functioning, Disability and Health. Factors associated with outcomes at 3–6 months, 9–12 months and beyond 12 months of index infection, for n > 500 individual participant data and > 1 data set were described using ratio of difference, point estimates, odds ratio and 95% confidence interval, as appropriate. The Mixed Methods Appraisal Tool described study quality; models were appraised using a Grading of Recommendations Assessment, Development and Evaluation-informed approach; heterogeneity was described using I 2 . Outcome measures: Included overall perception of health, multidomain cognitive function, anxiety, depression, stress, post-traumatic stress disorder, fatigue, strength, walking ability, mobility, coping with daily life, breathlessness, mortality, later hospitalisation and health-related quality of life. Results: PRECIOUS collated 116 data sets from 40 countries (individual participant data = 62,849), comprising 20 randomised controlled trials, 13 case-control, 60 cohort 2 longitudinal, 1 survey and 20 other study types. Participants’ median age was 58 years interquartile range (45–68); 34,185 (54.4%) were female; 158 unique symptoms and 137 unique assessment instruments were captured, predominantly describing International Classification of Function, Disability and Health-body functions. Women had poorer outcomes across 30/37 models, compared with men. In 15/37 models, pre-existing lung disease and increasing age were associated with poorer outcomes; hospitalisation, diabetes and chronic kidney disease were each associated with poorer outcomes in 8/37 models. Initial hospitalisation resulted in lower health-related quality of life that did not recover for up to 2 years after initial infection. Heterogeneity was low in 34/37 models; 22/37 models were of moderate and 11/37 were of low quality. Limitations: Use of secondary data limits available covariates, outcomes and time points to those included in primary data sets; evidence was primarily based on high-income countries. There was a lack of data on longer-term healthcare resource use to estimate the costs to the healthcare system. Conclusions: PRECIOUS contributes to the overall picture of long-term COVID-19 outcomes beyond the long-COVID condition and highlights poorer long-term outcomes in women and people with pre-existing comorbidities. Future work: Evidence gaps included healthcare resource use, isolation, loneliness, societal participation and return to work outcomes. Data are needed on the role of health inequity on long-term outcomes. Study registration: This study is registered as PROSPERO (CRD42020224323, IRAS ID: 293578). Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Health and Social Care Delivery Research programme (NIHR award ref: NIHR132895) and is published in full in Health and Social Care Delivery Research ; Vol. 14, No. 29. See the NIHR Funding and Awards website for further award information.
- 1 August 2026
- Published by National Institute for Health and Care Research in Health and Social Care Delivery Research
- p. 1-160
Open AccessIndividual Participant Data Meta-Analysis (IPDMA) of long-term COVID-19 outcomes in a systematic review-informed, international, multidisciplinary database
Background: Identifying and addressing long-term health and societal challenges after COVID-19 is a research priority. Objectives: To create an international, multidisciplinary COVID-19 database, and synthesise long-term outcomes, predictors and costs. Design: Systematic identification of COVID-19 data sets and meta-analysis of individual participant data on long-term outcomes after COVID-19. Setting: Contributed data were collected in clinical, community and research settings. Interventions: Interventions from original studies were included as covariates in models. Data sources: MEDLINE, Cochrane Central Register of Controlled Trials, EMBASE, Web of Science, PsycInfo ® (American Psychological Association, Washington, DC, USA), Cumulative Index to Nursing and Allied Health Literature, World Health Organization Global Index Medicus, Epistemonikos, LitCOVID; World Health Organization International Clinical Trials Registry Platform; ClinicalTrials.gov and supplementary searches for studies (November 2019–November 2021) were searched for studies on > 10 people from cohort, case-control, survey or randomised controlled trial studies, across any setting, describing validated assessment instruments, symptoms, hospitalisation, discharge destination or mortality beyond 28-days after COVID-19 onset. Data were extracted by two independent reviewers. Methods: Principal investigators contributed fully anonymised individual participant data. Demography, equity and symptoms were described. Assessment instruments were mapped to the International Classification of Functioning, Disability and Health. Factors associated with outcomes at 3–6 months, 9–12 months and beyond 12 months of index infection, for n > 500 individual participant data and > 1 data set were described using ratio of difference, point estimates, odds ratio and 95% confidence interval, as appropriate. The Mixed Methods Appraisal Tool described study quality; models were appraised using a Grading of Recommendations Assessment, Development and Evaluation-informed approach; heterogeneity was described using I 2 . Outcome measures: Included overall perception of health, multidomain cognitive function, anxiety, depression, stress, post-traumatic stress disorder, fatigue, strength, walking ability, mobility, coping with daily life, breathlessness, mortality, later hospitalisation and health-related quality of life. Results: PRECIOUS collated 116 data sets from 40 countries (individual participant data = 62,849), comprising 20 randomised controlled trials, 13 case-control, 60 cohort 2 longitudinal, 1 survey and 20 other study types. Participants’ median age was 58 years interquartile range (45–68); 34,185 (54.4%) were female; 158 unique symptoms and 137 unique assessment instruments were captured, predominantly describing International Classification of Function, Disability and Health-body functions. Women had poorer outcomes across 30/37 models, compared with men. In 15/37 models, pre-existing lung disease and increasing age were associated with poorer outcomes; hospitalisation, diabetes and chronic kidney disease were each associated with poorer outcomes in 8/37 models. Initial hospitalisation resulted in lower health-related quality of life that did not recover for up to 2 years after initial infection. Heterogeneity was low in 34/37 models; 22/37 models were of moderate and 11/37 were of low quality. Limitations: Use of secondary data limits available covariates, outcomes and time points to those included in primary data sets; evidence was primarily based on high-income countries. There was a lack of data on longer-term healthcare resource use to estimate the costs to the healthcare system. Conclusions: PRECIOUS contributes to the overall picture of long-term COVID-19 outcomes beyond the long-COVID condition and highlights poorer long-term outcomes in women and people with pre-existing comorbidities. Future work: Evidence gaps included healthcare resource use, isolation, loneliness, societal participation and return to work outcomes. Data are needed on the role of health inequity on long-term outcomes. Study registration: This study is registered as PROSPERO (CRD42020224323, IRAS ID: 293578). Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Health and Social Care Delivery Research programme (NIHR award ref: NIHR132895) and is published in full in Health and Social Care Delivery Research ; Vol. 14, No. 29. See the NIHR Funding and Awards website for further award information.
- 9 June 2026
- Published by Academician Publishing
- p. 235-246
Rekkürent Endometriomanın Yönetim
- 18 March 2026
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 321, 115049
Minimally invasive lateral suspension for pelvic organ prolapse: which route, laparoscopy or vNOTES?
- 18 March 2026
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 321, 115049
Minimally invasive lateral suspension for pelvic organ prolapse: which route, laparoscopy or vNOTES?
- Open Access
- 17 February 2026
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 26 (1)
A new removable uterine compression suture (RUCS) as an effective treatment for postpartum hemorrhage without long-term uterine synechiae: a retrospective preliminary study
Objectives: Uterine compression sutures have proven to be a valuable and safe option in the control of Postpartum hemorrhage. To avoid complications related to uterine compression sutures (uterine necrosis, synechia, and pyometra), we assess the efficacy of removable uterine compression suture (RUCS) for primary postpartum hemorrhage (PPH) and evaluate its effectiveness. Study design: This retrospective preliminary study was conducted at a tertiary referral hospital between January 2020 and November 2024, including patients diagnosed with postpartum hemorrhage who required compression sutures. Demographic characteristics of the patients who underwent RUCS and postpartum clinical parameters were determined. Results: Bleeding was successfully controlled in all 11 patients (100%). A mild, localized ecchymosis occurred at the unilateral suture exit site and resolved spontaneously. No intrauterine synechiae were detected in any of the 11 patients at 6-month hysteroscopic evaluation. Fertility outcomes were available for six women, five of whom achieved subsequent pregnancies. Conclusion: In this study, we present a novel removable compression suture that appears to be effective, simple, and rapid in application, with the potential to reduce serious complications; however, further evaluation is warranted.
- 17 February 2026
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 26 (1)
Open AccessA new removable uterine compression suture (RUCS) as an effective treatment for postpartum hemorrhage without long-term uterine synechiae: a retrospective preliminary study
Objectives: Uterine compression sutures have proven to be a valuable and safe option in the control of Postpartum hemorrhage. To avoid complications related to uterine compression sutures (uterine necrosis, synechia, and pyometra), we assess the efficacy of removable uterine compression suture (RUCS) for primary postpartum hemorrhage (PPH) and evaluate its effectiveness. Study design: This retrospective preliminary study was conducted at a tertiary referral hospital between January 2020 and November 2024, including patients diagnosed with postpartum hemorrhage who required compression sutures. Demographic characteristics of the patients who underwent RUCS and postpartum clinical parameters were determined. Results: Bleeding was successfully controlled in all 11 patients (100%). A mild, localized ecchymosis occurred at the unilateral suture exit site and resolved spontaneously. No intrauterine synechiae were detected in any of the 11 patients at 6-month hysteroscopic evaluation. Fertility outcomes were available for six women, five of whom achieved subsequent pregnancies. Conclusion: In this study, we present a novel removable compression suture that appears to be effective, simple, and rapid in application, with the potential to reduce serious complications; however, further evaluation is warranted.
- 31 December 2025
- Published by Elsevier in Journal of Minimally Invasive Gynecology
- Vol. 33 (4) , 440-449
Anatomic and Functional Outcomes After Vaginal Hysterectomy With Mesh-Based V-NOTES Lateral Suspension Versus Sacrospinous Ligament Fixation: A Randomized Controlled Trial
- 31 December 2025
- Published by Elsevier in Journal of Minimally Invasive Gynecology
- Vol. 33 (4) , 440-449
Anatomic and Functional Outcomes After Vaginal Hysterectomy With Mesh-Based V-NOTES Lateral Suspension Versus Sacrospinous Ligament Fixation: A Randomized Controlled Trial
- 21 November 2024
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 310 (6) , 3165-3171
Evaluation of uterocervical angle in intrauterine device displacement cases
Purpose Intrauterine device is one of the most preferred birth control method in the world. Being able to predict that the intrauterine device will not dislocate is very important in terms of preventing unwanted pregnancies. Here, we evaluated the role of uterocervical angle in displacement of intrauterine device and to determine whether it has a discriminative role for displacement. Methods This cross-sectional case–control study was conducted at an obstetrics and gynecology clinic of a university-affiliated training and research hospital. A total of 108 patients between June 2021 and September 2021 were included. While 36 patients in the case group had intrauterine device displacement, 72 patients in the control group had normal intracavitary intrauterine device detected under transvaginal ultrasound. Demographic characteristics, parameters related to intrauterine device and uterus were recorded. Uterocervical angle was measured in all the patients. Results There was no statistically significant difference in terms of sociodemographic features, parameters related to uterus size and intrauterine device. The median uterocervical angle was significantly higher in intrauterine device displacement group as compared to controls [159.5 (90–177) vs 146 (118–169) degrees, p < 0.001)]. Uterocervical angle > 156 degree discriminates intrauterine device displacement with 66.67% sensitivity and 80.56% specificity (AUC = 0.763). Conclusion A larger uterocervical angle may suggest an increased likelihood of intrauterine device displacement. Thus, uterocervical angle seems to have a potential to play a crucial role in the monitoring and management of intrauterine device users even in patients with similar sized uterus.
- 21 November 2024
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 310 (6) , 3165-3171
Evaluation of uterocervical angle in intrauterine device displacement cases
Purpose Intrauterine device is one of the most preferred birth control method in the world. Being able to predict that the intrauterine device will not dislocate is very important in terms of preventing unwanted pregnancies. Here, we evaluated the role of uterocervical angle in displacement of intrauterine device and to determine whether it has a discriminative role for displacement. Methods This cross-sectional case–control study was conducted at an obstetrics and gynecology clinic of a university-affiliated training and research hospital. A total of 108 patients between June 2021 and September 2021 were included. While 36 patients in the case group had intrauterine device displacement, 72 patients in the control group had normal intracavitary intrauterine device detected under transvaginal ultrasound. Demographic characteristics, parameters related to intrauterine device and uterus were recorded. Uterocervical angle was measured in all the patients. Results There was no statistically significant difference in terms of sociodemographic features, parameters related to uterus size and intrauterine device. The median uterocervical angle was significantly higher in intrauterine device displacement group as compared to controls [159.5 (90–177) vs 146 (118–169) degrees, p < 0.001)]. Uterocervical angle > 156 degree discriminates intrauterine device displacement with 66.67% sensitivity and 80.56% specificity (AUC = 0.763). Conclusion A larger uterocervical angle may suggest an increased likelihood of intrauterine device displacement. Thus, uterocervical angle seems to have a potential to play a crucial role in the monitoring and management of intrauterine device users even in patients with similar sized uterus.
- 12 March 2024
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 50 (5) , 856-863
Evaluation of the parameters in predicting single‐dose methotrexate therapy success for ectopic pregnancy
Aim: Methotrexate has demonstrated efficacy in treating ectopic pregnancies. This study explores factors influencing treatment success, focusing on laboratory and ultrasonographic findings, particularly the day 4 to day 1 β‐hCG level ratio.Methods: Retrospective cohort study was conducted within patients diagnosed with tubal ectopic pregnancy. Patients' characteristics, ultrasound findings, laboratory data, and β‐hCG levels (days 1, 4, 7), and operation findings were reviewed. Women's characteristics were investigated who were treated with single dose of MTX (50 mg/m2). Patients who were performed surgery after MTX treatment were identified as MTX treatment failure.Results: Among 439 women, 259 underwent surgery due to acute symptoms. Of those treated with MTX, 143 experienced treatment success, while 37 underwent surgery after MTX (MTX failure). Comparative analysis revealed significant differences in β‐hCG levels on admission (1128 and 4125 mIU/mL) and the day 4 to day 1 β‐hCG ratio (0.91 and 1.25). The overall MTX success rate was 79%, reaching 93% and 89% for β‐hCG levels <1000 mIU/mL and <2000 mIU/mL, respectively. Success dropped to 50% with levels exceeding 5000 mIU/mL. ROC analysis identified a crucial 2255 mIU/mL cut‐off for β‐hCG (sensitivity 70.3% and specificity 68.5%) and a day 4 to day 1 β‐hCG ratio of 95.5% (sensitivity 84.7%, specificity 72.5%, positive predictive value 75.4%) for predicting MTX success.Conclusion: Establishing a β‐hCG cutoff can reduce hospital stay. The day 4 to day 1 β‐hCG ratio holds promise as a widely applicable predictor for MTX success or for determining MTX administration on day 4.
- 12 March 2024
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 50 (5) , 856-863
Evaluation of the parameters in predicting single‐dose methotrexate therapy success for ectopic pregnancy
Aim: Methotrexate has demonstrated efficacy in treating ectopic pregnancies. This study explores factors influencing treatment success, focusing on laboratory and ultrasonographic findings, particularly the day 4 to day 1 β‐hCG level ratio.Methods: Retrospective cohort study was conducted within patients diagnosed with tubal ectopic pregnancy. Patients' characteristics, ultrasound findings, laboratory data, and β‐hCG levels (days 1, 4, 7), and operation findings were reviewed. Women's characteristics were investigated who were treated with single dose of MTX (50 mg/m2). Patients who were performed surgery after MTX treatment were identified as MTX treatment failure.Results: Among 439 women, 259 underwent surgery due to acute symptoms. Of those treated with MTX, 143 experienced treatment success, while 37 underwent surgery after MTX (MTX failure). Comparative analysis revealed significant differences in β‐hCG levels on admission (1128 and 4125 mIU/mL) and the day 4 to day 1 β‐hCG ratio (0.91 and 1.25). The overall MTX success rate was 79%, reaching 93% and 89% for β‐hCG levels <1000 mIU/mL and <2000 mIU/mL, respectively. Success dropped to 50% with levels exceeding 5000 mIU/mL. ROC analysis identified a crucial 2255 mIU/mL cut‐off for β‐hCG (sensitivity 70.3% and specificity 68.5%) and a day 4 to day 1 β‐hCG ratio of 95.5% (sensitivity 84.7%, specificity 72.5%, positive predictive value 75.4%) for predicting MTX success.Conclusion: Establishing a β‐hCG cutoff can reduce hospital stay. The day 4 to day 1 β‐hCG ratio holds promise as a widely applicable predictor for MTX success or for determining MTX administration on day 4.
- Open Access
- 26 October 2023
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 53 (5) , 1498-1504
Serum myosin-binding protein c levels: a new marker for exclusion of preterm birth?
Background/aim: To evaluate whether there is a relationship between serum myosin-binding protein C (MyBP-C) levels measured in the first trimester and the timing of delivery, and, if a relationship is detected, the potential of this relationship in distinguishing between preterm and term labor. Materials and methods: This prospective case-control study was conducted with 701 pregnant women who applied to the Obstetrics Outpatient Clinic of Gaziosmanpaşa Training and Research Hospital in the first trimester, between 11 and 14 gestational weeks. MyBP-C serum samples from the first trimester were stored under appropriate conditions until the time of delivery. Of these pregnant women, 628 completed the study. According to the delivery time, the pregnant women were divided into two groups, as those who delivered prematurely before 37 weeks and those who gave birth at term. The case group comprised 45 women who gave birth prematurely, while 583 women gave birth at term. A control group was formed with 45 pregnant women of the same age, who were selected by randomization using a simple random sampling method from the 583 pregnant women. The MyBP-C levels were measured and compared from the first-trimester serum materials of both groups. Results: The MyBP-C levels of the preterm delivery group were significantly higher than those of the term delivery control group (4.51 ± 1.69 vs. 3.09 ± 1.44 pg/mL, respectively; p < 0.001). Receiver operating characteristic (ROC) curve analysis showed that the MyBP-C levels in the first trimester with a cut-off value of 4.76 ng/dL indicated women with preterm delivery with a sensitivity of 42.22% and specificity of 95.56% (AUC: 0.734, 95% CI: 0.630?0.822). The overall differential diagnosis performance of the MyBP-C level for preterm delivery was determined as 73.4% (p < 0.001). The MyBP-C levels were found to be significantly higher both in the early preterm group compared with the late preterm group (p < 0.001), and in those with premature rupture of membranes (PROM) compared with those without (p < 0.001). Conclusion: The preterm delivery group exhibited high serum MyBP-C levels in the serum samples taken in the first trimester. Firsttrimester serum MyBP-C levels seem to be a simple and easy way to exclude preterm delivery risk in a significant manner. In addition, levels are significantly higher for early preterm compared with late preterm and early PROM compared with intact membranes.
- 26 October 2023
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 53 (5) , 1498-1504
Open AccessSerum myosin-binding protein c levels: a new marker for exclusion of preterm birth?
Background/aim: To evaluate whether there is a relationship between serum myosin-binding protein C (MyBP-C) levels measured in the first trimester and the timing of delivery, and, if a relationship is detected, the potential of this relationship in distinguishing between preterm and term labor. Materials and methods: This prospective case-control study was conducted with 701 pregnant women who applied to the Obstetrics Outpatient Clinic of Gaziosmanpaşa Training and Research Hospital in the first trimester, between 11 and 14 gestational weeks. MyBP-C serum samples from the first trimester were stored under appropriate conditions until the time of delivery. Of these pregnant women, 628 completed the study. According to the delivery time, the pregnant women were divided into two groups, as those who delivered prematurely before 37 weeks and those who gave birth at term. The case group comprised 45 women who gave birth prematurely, while 583 women gave birth at term. A control group was formed with 45 pregnant women of the same age, who were selected by randomization using a simple random sampling method from the 583 pregnant women. The MyBP-C levels were measured and compared from the first-trimester serum materials of both groups. Results: The MyBP-C levels of the preterm delivery group were significantly higher than those of the term delivery control group (4.51 ± 1.69 vs. 3.09 ± 1.44 pg/mL, respectively; p < 0.001). Receiver operating characteristic (ROC) curve analysis showed that the MyBP-C levels in the first trimester with a cut-off value of 4.76 ng/dL indicated women with preterm delivery with a sensitivity of 42.22% and specificity of 95.56% (AUC: 0.734, 95% CI: 0.630?0.822). The overall differential diagnosis performance of the MyBP-C level for preterm delivery was determined as 73.4% (p < 0.001). The MyBP-C levels were found to be significantly higher both in the early preterm group compared with the late preterm group (p < 0.001), and in those with premature rupture of membranes (PROM) compared with those without (p < 0.001). Conclusion: The preterm delivery group exhibited high serum MyBP-C levels in the serum samples taken in the first trimester. Firsttrimester serum MyBP-C levels seem to be a simple and easy way to exclude preterm delivery risk in a significant manner. In addition, levels are significantly higher for early preterm compared with late preterm and early PROM compared with intact membranes.
- 5 August 2023
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 309 (6) , 2633-2641
Comparing elective and emergency caesarean section by using bioimpedance method
Background There are limited studies focusing on hemodynamic changes between elective and emergent C/S cases. We considered that a better understanding of the alterations and physiological reactions in both situations with non-invasive novel technologies might be useful in managing maternal and fetal sides. Methods In this prospective observational study, non-invasive hemodynamic changes were observed by using the whole-body impedance method using the NICaS™ device. CO, cardiac index (CI), stroke volume (SV), stroke index (SI), total peripheric resistance (TPR), and cardiac reserve (GGI) parameters were evaluated with a non-invasive method. Measurements were done initiating before surgery, 9 times of 5 min intervals. Results All 95 patients finished the study. 47 cesarean sections were in the elective group, 48 were in the emergent group. SV in 4.5.6. time intervals were statistically increased in the elective group (p values: SvMl4: 0.025, SvMl5: 0.049, SvMl6: 0.044) (p < 0.05). SI in the second-time interval was statistically increased in the emergent group (p-value SI2: 0.047) (p < 0.05). SI in the 4th time interval was statistically increased in the elective group (p-value SI4: 0.047) (p < 0.05). CO measurements were not statistically different between groups in all time intervals for all comparisons. CI in the second time interval was statistically decreased in the elective group (p-value CI2: 0.012) (p < 0.05). GGI in the 4th time interval was statistically increased in the elective group (p-value GGI4: 0.035) (p < 0.05). TPRI in the second time interval was statistically increased in the elective group (p-value TPRI 2: 0.014) (p < 0.05). Conclusions Understanding normal hemodynamic values before, during, and after C/S is feasible and might help the clinician assess patients’ cardiac performance with a reliable noninvasive technique. NICaS might be a reliable tool to evaluate patients’ baseline values and diagnose complications earlier during the surgery.
- 5 August 2023
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 309 (6) , 2633-2641
Comparing elective and emergency caesarean section by using bioimpedance method
Background There are limited studies focusing on hemodynamic changes between elective and emergent C/S cases. We considered that a better understanding of the alterations and physiological reactions in both situations with non-invasive novel technologies might be useful in managing maternal and fetal sides. Methods In this prospective observational study, non-invasive hemodynamic changes were observed by using the whole-body impedance method using the NICaS™ device. CO, cardiac index (CI), stroke volume (SV), stroke index (SI), total peripheric resistance (TPR), and cardiac reserve (GGI) parameters were evaluated with a non-invasive method. Measurements were done initiating before surgery, 9 times of 5 min intervals. Results All 95 patients finished the study. 47 cesarean sections were in the elective group, 48 were in the emergent group. SV in 4.5.6. time intervals were statistically increased in the elective group (p values: SvMl4: 0.025, SvMl5: 0.049, SvMl6: 0.044) (p < 0.05). SI in the second-time interval was statistically increased in the emergent group (p-value SI2: 0.047) (p < 0.05). SI in the 4th time interval was statistically increased in the elective group (p-value SI4: 0.047) (p < 0.05). CO measurements were not statistically different between groups in all time intervals for all comparisons. CI in the second time interval was statistically decreased in the elective group (p-value CI2: 0.012) (p < 0.05). GGI in the 4th time interval was statistically increased in the elective group (p-value GGI4: 0.035) (p < 0.05). TPRI in the second time interval was statistically increased in the elective group (p-value TPRI 2: 0.014) (p < 0.05). Conclusions Understanding normal hemodynamic values before, during, and after C/S is feasible and might help the clinician assess patients’ cardiac performance with a reliable noninvasive technique. NICaS might be a reliable tool to evaluate patients’ baseline values and diagnose complications earlier during the surgery.